Banque Cantonale Vaudoise Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Banque Cantonale Vaudoise boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 69.5% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 1,970 shares of the biopharmaceutical company’s stock after acquiring an additional 808 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Regeneron Pharmaceuticals were worth $1,522,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Focused Wealth Management Inc purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter worth approximately $297,000. CENTRAL TRUST Co boosted its stake in shares of Regeneron Pharmaceuticals by 43.1% in the first quarter. CENTRAL TRUST Co now owns 1,075 shares of the biopharmaceutical company’s stock worth $831,000 after acquiring an additional 324 shares during the last quarter. Cora Capital Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 36.0% during the first quarter. Cora Capital Advisors LLC now owns 359 shares of the biopharmaceutical company’s stock worth $277,000 after purchasing an additional 95 shares in the last quarter. Cidel Asset Management Inc. increased its position in shares of Regeneron Pharmaceuticals by 22.1% during the first quarter. Cidel Asset Management Inc. now owns 719 shares of the biopharmaceutical company’s stock worth $556,000 after purchasing an additional 130 shares in the last quarter. Finally, Athena Wealth Management LLC raised its stake in Regeneron Pharmaceuticals by 68.1% in the 1st quarter. Athena Wealth Management LLC now owns 990 shares of the biopharmaceutical company’s stock valued at $765,000 after purchasing an additional 401 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the transaction, the director owned 17,503 shares of the company’s stock, valued at $12,343,815.72. This trade represents a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $632.90 on Friday. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 52 week low of $517.39 and a 52 week high of $821.11. The firm’s 50 day moving average is $663.51 and its two-hundred day moving average is $728.45. The firm has a market capitalization of $66.91 billion, a P/E ratio of 15.42, a P/E/G ratio of 1.36 and a beta of 0.25.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. During the same period in the previous year, the company earned $8.22 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 19.0% compared to the same quarter last year. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were paid a dividend of $0.94 per share. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is 9.16%.

Analyst Ratings Changes

REGN has been the subject of a number of research reports. Citigroup lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $900.00 to $700.00 in a report on Monday, May 18th. Sanford C. Bernstein decreased their target price on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 8th. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Piper Sandler cut their price target on Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating for the company in a report on Monday, May 18th. Finally, TD Cowen boosted their price objective on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a research note on Thursday, April 23rd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $792.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.